Abbott: Bear Trap Over, With Richer Return Prospects

ABT's diversified diagnostics/nutrition/medtech segments drive multi-pronged growth prospects, as the management targets a +7% organic growth rate. The recent EXAS acquisition introduces balance sheet/bottom-line risks, albeit with the new Cancer Diagnostic segment delivering double-digit growth rates. The prior meltdown unlocks the cheap valuations, the richer dividend yields, and the excellent upside potential to my bull-case LTPT of $139. ABT remains a great Buy here, albeit with near-term underperformance risks entering the seasonally softer Q3 trading months.

I previously rated Abbott Laboratories (ABT) as a Buy in February 2026, thanks to the cheap valuations and the accelerating bottom-line growth prospects. In this article, I shall discuss why ABT remains a buy for